转移性黑色素瘤患者体重指数与靶向治疗、免疫治疗或化疗结局的关联:一项回顾性多队列分析
这项回顾性多队列分析纳入6个队列共1918例转移性黑色素瘤患者,按WHO标准根据BMI分类,评估BMI与无进展生存期和总生存期的关联。该生存获益主要见于接受靶向治疗或免疫治疗的患者,化疗组未见关联;
要点
- 肥胖与转移性黑色素瘤靶向或免疫治疗患者更好的PFS和OS相关。
- 化疗患者中未观察到BMI与生存结局的关联。
- 靶向/免疫治疗中BMI与OS的关联存在性别差异,仅男性显著。
核心结论
- 在转移性黑色素瘤患者中,肥胖与更好的无进展生存期和总生存期相关,该关联主要见于接受靶向或免疫治疗的男性患者。
研究设计与样本
- 回顾性多队列分析,纳入6个独立队列共2046例患者,最终分析1918例。
- 队列包括靶向治疗(达拉非尼联合曲美替尼 n=599;维莫非尼联合考比替尼 n=240)、免疫治疗(伊匹木单抗联合达卡巴嗪随机对照试验 n=207;帕博利珠单抗、纳武利尤单抗或阿替利珠单抗回顾性队列 n=331)和化疗(达卡巴嗪随机对照试验 n=320和n=221)。
- 按WHO标准将BMI分类为正常(694例,36%)、超重(711例,37%)和肥胖(513例,27%),排除无BMI及体重过低患者。
- 主要结局为按治疗类型和性别分层的BMI与无进展生存期或总生存期的关联,采用多变量分析和混合效应荟萃分析合并校正风险比。
临床怎么用
- 在转移性黑色素瘤接受靶向或免疫治疗时,肥胖( vs 正常BMI)与更好的生存相关,尤其男性患者,可考虑作为预后因素。
- 化疗患者中BMI与生存无关,不应据此调整治疗选择。
局限性
- 本研究为回顾性分析,存在固有偏倚。
- 肥胖与生存获益的关联机制尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy. METHODS: This retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy. Patients were classified according to BMI, following the WHO definitions, as underweight, normal, overweight, or obese. Patients without BMI and underweight patients were excluded. The primary outcomes were the associations between BMI and progression-free survival or overall survival, stratified by treatment type and sex. We did multivariable analyses in the independent cohorts, and combined adjusted hazard ratios in a mixed-effects meta-analysis to provide a precise estimate of the association between BMI and survival outcomes; heterogeneity was assessed with meta-regression analyses. Analyses were done on the predefined intention-to-treat population in the randomised controlled trials and on all patients included in the retrospective study. FINDINGS: The six cohorts consisted of a total of 2046 patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy between Aug 8, 2006, and Jan 15, 2016. 1918 patients were included in the analysis. Two cohorts containing patients from randomised controlled trials treated with targeted therapy (dabrafenib plus trametinib [n=599] and vemurafenib plus cobimetinib [n=240]), two cohorts containing patients treated with immunotherapy (one randomised controlled trial of ipilimumab plus dacarbazine [n=207] and a retrospective cohort treated with pembrolizumab, nivolumab, or atezolizumab [n=331]), and two cohorts containing patients treated with chemotherapy (two randomised controlled trials of dacarbazine [n=320 and n=221]) were classified according to BMI as normal (694 [36%] patients), overweight (711 [37%]), or obese (513 [27%]). In the pooled analysis, obesity, compared with normal BMI, was associated with improved survival in patients with metastatic melanoma (average adjusted hazard ratio [HR] 0·77 [95% CI 0·66-0·90] for progression-free survival and 0·74 [0·58-0·95] for overall survival). The survival benefit associated with obesity was restricted to patients treated with targeted therapy (HR 0·72 [0·57-0·91] for progression-free survival and 0·60 [0·45-0·79] for overall survival) and immunotherapy (HR 0·75 [0·56-1·00] and 0·64 [0·47-0·86]). No associations were observed with chemotherapy (HR 0·87 [0·65-1·17, pinteraction=0·61] for progression-free survival and 1·03 [0·80-1·34, pinteraction=0·01] for overall survival). The association of BMI with overall survival for patients treated with targeted and immune therapies differed by sex, with inverse associations in men (HR 0·53 [0·40-0·70]), but no associations observed in women (HR 0·85 [0·61-1·18, pinteraction=0·03]). INTERPRETATION: Our results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations. FUNDING: ASCO/CCF Young Investigator Award, ASCO/CCF Career Development Award, MD Anderson Cancer Center (MDACC) Melanoma Moonshot Program, MDACC Melanoma SPORE, and the Dr Miriam and Sheldon G Adelson Medical Research Foundation.
引用
- McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018. PMID: 29449192. doi:10.1016/S1470-2045(18)30078-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。